Connect with us on the social channels
Press Releases
- DCprime Presents Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 7 December, 2020Phase II Data for DCprime’s Cell-based Cancer Relapse Vaccine Shows the Potential to Successfully Control Residual Disease as the Basis for a Prolonged Remission in AML Leiden, The Netherlands, December 7, 2020 – DCprime, the front-runner in the field of relapse vaccines, published interim results from its ongoing Phase II study (ADVANCE II, Clintrials.gov: NCT03697707) in …Read More
- DCprime Presents Preclinical Data at SITC 2020 Validating the Use of its Cell-based Cancer Relapse Vaccine in Ovarian Cancer 9 November, 2020Results demonstrate that the company’s lead vaccine candidate can direct a comprehensive immune response against ovarian tumor cells and induce the formation of memory T cells Leiden, The Netherlands, November 9, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical results at the virtual 35th Annual Meeting of …Read More
- DCprime to Present Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting 5 November, 2020Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The Interim data on both primary …Read More
- DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms 21 September, 2020Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 – DCprime, the front-runner in the field of relapse vaccines, and Glycotope GmbH, a clinical-stage oncology/immuno-oncology company built on world-leading glycobiology expertise, today announced an expansion of their existing partnership through a new research collaboration and licensing agreement. Originally initiated in July 2018, the partnership combines DCprime’s …Read More
- DCprime and PCI Biotech Announce a Research Collaboration to Explore Novel Cancer Vaccination Concepts 1 September, 2020Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech will combine their know-how and …Read More
- DCprime and University of Bergen Present Data on Novel Animal Model for Cancer Vaccine Research 12 June, 2020Presentation at EHA Congress reviews development of a humanized immunocompetent mouse model to study DCP-001 as a vaccine for leukemia Leiden, The Netherlands, June 12, 2020 –DCprime, the front-runner in the field of relapse vaccines, in collaboration with the University of Bergen, today announced the presentation of a novel preclinical animal model tailored for cancer vaccine …Read More
- DCprime Extends International Roll-out of DCP-001 Into the United States 13 May, 2020Opening of IND follows approval to study DCP-001 in multiple European countries Leiden, The Netherlands, May 13, 2020 –DCprime, the front-runner in the field of relapse vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for DCP-001, an allogeneic cancer relapse vaccine currently being evaluated …Read More
- DCprime Receives US FDA Orphan Drug Designation for DCP-001 in Acute Myeloid Leukemia 5 December, 2019Leiden, The Netherlands, December 05, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCP-001 for the treatment of acute myeloid leukemia (AML). DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse …Read More
- DCprime to Present Long-term Follow-up and Survival Data for Lead Relapse Vaccine Candidate DCP-001 in High-Risk AML and MDS Patients 13 November, 2019Presentation at ASH Annual Meeting Shows Potential to Prolong Relapse-Free Survival and Overall Survival Using an Allogeneic Cell-based Vaccine in the Post-Remission Setting Leiden, The Netherlands, November 13, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of updated clinical results for its lead product DCP-001 at the upcoming 61st Annual …Read More
- DCprime Presents Preclinical Data on Novel Vaccination Concept Using the DCOne® Cell Line in Solid Tumour Models 6 November, 2019Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen Leiden, The Netherlands, November 6, 2019 –DCprime, the front-runner in the field of relapse vaccines, today announced the presentation of preclinical proof-of-concept results at the 34th Annual …Read More
Dr Ada Kruisbeek resigns as CSO, assumes role as Chair of the Scientific Advisory Board
Leiden, The Netherlands, January 2019 – DCprime announces that Dr Ada Kruisbeek, founder, CSO and former CEO of the company, has resigned from her acting role as CSO per January 1, 2019. DCprime has appointed Dr Kruisbeek as Chair of the company’s Scientific Advisory Board. Dr Kruisbeek founded DCprime in
DCprime announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia
Leiden, The Netherlands, 15 November 2018 – DCprime bv, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but
Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer
Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different
Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy
Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer
DCprime and Glycotope announce licensing agreement and collaboration
DCprime and Glycotope announce licensing agreement and collaboration Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime bv, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have
DCprime announces that Erik Manting PhD will join the company as its CEO
Leiden, The Netherlands, March 01, 2018 – DCprime announces today that Erik Manting PhD will become DCprime’s new Chief Executive Officer with immediate effect. Dr Manting succeeds Ada Kruisbeek, who will remain committed to DCprime as Chief Scientific Officer. Prior to joining DCprime, Erik spent 15 years in different management
DCOne® induces immune responses against Multiple Myeloma
Leiden, The Netherlands – DCPrime B.V., a clinical stage company dedicated to developing cancer vaccines based on its proprietary DCOne® platform, announces the publication of a peer-reviewed research paper which documents that its lead product DCP-001 can induce T cell activation and myeloma-specific immunity in peripheral blood mononuclear cells from